Corbus Pharmaceuticals Reports Second Quarter Financial Results and Corporate Updates
August 06, 2020 07:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
RESOLVE-1 Phase 3 study of lenabasum for treatment of systemic sclerosis on schedule for topline data this summerPhase 2b study of lenabasum for cystic fibrosis topline results on schedule in Q3...
Corbus Pharmaceuticals Completes Enrollment in DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis
August 05, 2020 09:25 ET
|
Corbus Pharmaceuticals Holdings, Inc.
12-month, double-blind, placebo-controlled, multi-national study enrolled 176 participantsTopline results expected in fourth quarter of 2021 Dermatomyositis is a rare, systemic autoimmune disease with...
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences
August 03, 2020 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Norwood, MA, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative...
Corbus Pharmaceuticals to Report Second Quarter Results on August 6, 2020
July 30, 2020 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Management to host conference call and webcast on Thursday, August 6 at 8:30 a.m. ET Norwood, MA, July 30, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus”...
Corbus Pharmaceuticals Strengthens Balance Sheet with up to $121 Million in New Capital
July 29, 2020 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Aggregate of $71 million of ATM proceeds executed at weighted average price of $7.70 per shareReceived $20 million first tranche from $50 million debt facility with K2 HealthVentures Cash on hand of...
Corbus Pharmaceuticals Appoints George Golumbeski, Ph.D., to Board of Directors
July 08, 2020 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Dr. Golumbeski formerly led corporate and business development at Celgene and NovartisAppointment adds unique skill set to Corbus Board ahead of several key data readouts this summer Norwood, MA,...
Corbus Pharmaceuticals Presents Data Demonstrating ACR CRISS Score Reflects Patient-Reported Outcomes at 6th Systemic Sclerosis World E-Congress
June 29, 2020 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Phase 2 systemic sclerosis (SSc) analyses show ACR CRISS score correlates with improvements from baseline in how patients feel and function through two years in the lenabasum Phase 2 open-label...
Corbus Pharmaceuticals Reports Last Subject Visit in Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis
June 22, 2020 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Topline data on schedule for Q3 2020Reduction in pulmonary exacerbations (PEx) as primary endpoint Study enrolled 426 participants regardless of CFTR mutation or background CFTR-targeting...
Corbus Pharmaceuticals Announces Publication of Phase 2b Cystic Fibrosis Study Patient Demographics and Baseline Disease Characteristics in the Journal of Cystic Fibrosis
June 01, 2020 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Phase 2b study of lenabasum for treatment of cystic fibrosis enriched for patients at high risk of pulmonary exacerbationsStudy on target for data readout in late summer 2020 Norwood, MA, June ...
Corbus Pharmaceuticals Reports Last Subject Visit in RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis
May 27, 2020 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Topline data on schedule for summer 2020Systemic sclerosis (SSc) is a rare, serious and life-threatening autoimmune disease affecting ~200,000 people in the U.S., EU and JapanThere are no FDA-approved...